Fighting cancer one cell at a time

Google+ Pinterest LinkedIn Tumblr +

A team of scientists from Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) has identified a new approach to cancer therapeutics by targeting the evolution of cancer cells. This approach prevents or delays the progression of cancer into treatment-resistant/metastatic disease. The study was published in Nature Communications on 22 November 2018.

Traditional approaches to cancer treatment have primarily focused on complete elimination of cancer cells. They treat patients with high doses of chemotherapy to target the highly proliferative tumour cells. However, it is increasingly clear that like any other living being, cancer cells also follow the basic evolutionary principles and will adapt to survive.

This study employed single-cell genomics and patient-derived primary cell (PDPC) models to identify the different modes that cause cancer cells to become resistant or metastatic. The scientists observed that in some patients, the cancer cells kept multiplying even when treated with high doses of the drug. Researchers theorise that the cells were switching their stem cell factors upon treatment, making them drug resistant.

“The cancer cells behave like chameleons, altering their gene expression and cell behaviour to overcome drug treatment. A comprehensive understanding of tumour evolution and our ability to predict cancer’s next evolutionary move can serve as a way forward to manage therapy resistance in the clinic,” said Dr. Ankur Sharma, first author of the study and Research Associate at GIS.

Dr. Ramanuj DasGupta, senior author of the study and Group Leader at GIS, added, “Like a game of whack-a-mole, cancer cells have a long history of finding alternative routes to evade treatment. By targeting the tumour evolution itself, we aim to prevent or at least delay its progression, and at the same time, avoid the harsh effects of excessive treatment.”

Further investigations identified the BRD4 gene as a key molecule for resistance. They then treated the resistant cells with JQ1, a drug known to block BRD4 activity, and were able to reverse or delay drug-resistance in tumour cells.

Professor William Hwang, Medical Director at National Cancer Centre Singapore, said, “The findings could help us identify patients with cancer who are at the highest risk of having treatment-resistant relapse, as well as suggest some ways that we can better treat these patients when they relapse. We look forward to being able to translate this into clinical practice in the near future.”

Professor Ng Huck Hui, Executive Director at GIS, said, “Tumour cells are constantly evolving. We need to adopt new strategies of evolutionary precision medicine to target them with the right drugs. Targeting the cancer’s evolution itself has the potential to convert this dreaded disease into something that can be chronically managed, and this study is the first step towards that goal.”

Paper: Ankur Sharma et al. Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy, Nature Communications (2018). DOI: 10.1038/s41467-018-07261-3


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.